Engineered Cardiomyocytes Attenuate Engraftment Arrhythmia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cardiac cell therapies using primary cardiomyocytes or differentiated cardiomyocytes from pluripotent cells often result in engraftment arrhythmia (EA), and current pharmacological and genetic approaches to mitigate EA are either ineffective or come with unwanted side effects.
Innovation Solution
Engineered cells with specific modifications that reduce expression of CACNA1G, HCN4, and SLC8A1, and increase expression of KCNJ2, TRDN, SRL, HRC, and CASQ2, are developed to attenuate or prevent engraftment arrhythmia in cardiac cell therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If primary cardiomyocytes or differentiated cardiomyocytes are used for cardiac cell therapy, then the therapy can be administered, but engraftment arrhythmia occurs reducing treatment efficacy
Solution Approach 1:
The patent applies preliminary action by genetically modifying cardiomyocytes before transplantation to alter ion channel expression profiles. Specifically, the cells are pre-engineered with reduced expression of CACNA1G, HCN4, and SLC8A1 genes, and increased expression of KCNJ2, TRDN, SRL, HRC, and CASQ2 genes. This preliminary genetic conditioning prevents arrhythmogenicity from developing after engraftment, thereby maintaining treatment efficacy without the harmful side effect of engraftment arrhythmia.
Solution Approach 2:
The patent implements parameter changes by systematically altering the expression levels of multiple ion channel-related genes in cardiomyocytes. The modified cells exhibit changed electrical properties due to reduced CACNA1G (L-type calcium channel), HCN4 (hyperpolarization-activated current), and SLC8A1 (sodium-calcium exchanger) expression, combined with increased KCNJ2 (inward rectifier potassium current), TRDN (ryanodine receptor), SRL (sarcoplasmic reticulum calcium ATPase), HRC (calsequestrin), and CASQ2 (calcium storage protein) expression. These parameter changes in gene expression directly prevent the development of arrhythmia while preserving therapeutic function.
2Object-affected harmful factors
If pharmacological agents are used to attenuate engraftment arrhythmia, then some protection may be achieved, but unwanted side effects occur
Solution Approach 1:
The patent extracts the harmful arrhythmogenic properties from cardiomyocytes through genetic modification rather than using pharmacological agents. By removing or reducing the expression of specific ion channel genes (CACNA1G, HCN4, SLC8A1) that contribute to arrhythmia susceptibility, the therapy achieves protection against engraftment arrhythmia without introducing the side effects associated with drug treatments. The genetic modification selectively removes the problematic electrical properties while preserving essential cardiac functions.
3Object-affected harmful factors
If genetic engineering is used to prevent engraftment arrhythmia, then arrhythmia reduction is achieved, but the engineering complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the genetic modification task into distinct functional modules: reducing expression of three arrhythmia-associated genes (CACNA1G, HCN4, SLC8A1) and increasing expression of five protective genes (KCNJ2, TRDN, SRL, HRC, CASQ2). This segmented approach to genetic engineering allows systematic modification of ion channel properties to prevent arrhythmia while maintaining manageable engineering complexity through modular gene target selection.
Data Source
AI summary
Provided are engineered cells containing one or more modifications, such as genetic modifications, for use in cardiac cell therapies. In some embodiments, the one or more modifications attenuate or prevent engraftment arrhythmia associated with a cardiac cell therapy.